USDA launches new initiatives to combat antibiotics resistance; Nexvet nabs Novartis vet for board chair; bird flu continues its spread;

> The USDA is seeking federal funding to begin surveying livestock producers on their use of antibiotics. Article

> The USDA's National Institute of Food and Agriculture has awarded $19 million in food-safety research grants, including $6.7 million devoted to combating antibiotics resistance. Release

> Nexvet Biopharma ($NVET) appointed Novartis ($NVS) Animal Health veteran George Gunn as nonexecutive chairman of its board of directors. Release

> The H5N2 strain of bird flu has spread to a fifth Minnesota turkey farm, as well as a commercial turkey facility in South Dakota. Article

> The FDA and the North Carolina Board of Pharmacy warned all health professionals, including veterinarians, not to use products made by the Prescription Center, a compounding pharmacy in Fayetteville, NC, that was recently shut down. Release

> Milestone Scientific ($MLSS) has joined with Mila International to develop and commercialize a device for performing maxillary nerve block procedures in horses. Release

> National Enzyme Company of Branson, MO, has launched a new subsidiary, American Animal Nutrition, which is marketing supplements to the equine industry. Release

> Merck ($MRK) Animal Health awarded $170,000 in scholarships to 34 second- and third-year veterinary students. Release

> MEP Equine Solutions of Lexington, KY, received a $100,000 Small Business Innovation Research grant from the USDA to complete a Phase I trial of a smartphone app designed to detect parasites. Release

> Michael P. Ferry Inc., a dairy producer in Westport, MA, agreed to a permanent injunction after a USDA inspection uncovered residues of illegal drugs in animals sold for human consumption. Release

Suggested Articles

Pfizer spinoff Zoetis met Q2 expectations and brightened its full-year forecast, but it's looking to M&A to drive further growth.

Fresenius’ new CEO has pulled off a dealmaking double play, committing more than $5.4 billion to expand its reach in both sterile generics and in biosimilars.

Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. But with the big Monsanto merger top of mind at Bayer…